FDA Draft PGx Guidance Urges Early Planning to Anticipate Pre-market Gene-Drug Issues

The agency hopes the guidance can lay out a path for drug developers to identify PGx issues before a drug enters the market, instead of emerging PGx data changing the treatment's risk/benefit profile in the post-market setting.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.